VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain Tumors

VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain Tumors - VEGFR 1/2 Peptide Vaccine for Recurrent, Progressive and Refractory Brain Tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029005

Enrollment

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent, Progressive and Refractory Brain Tumors(hemangiopericytoma, hemangioblastoma, WHO grade II or III meningioma, chordoma, ependymoma)

Interventions

Subcutaneous injection of VEGFR1 and VEGFR2 peptides (2mg, respectively) with IFA. Weekly administration, 4 times and then monthly administration, 4 times

total 8 times.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) recurrent, progressive and refractory brain tumors (hemangiopericytoma, hemangioblastoma, WHO grade II or III meningioma, chordoma, ependymoma) without surgical and radiorogical justification 2) announcement of a diagnosis 3) HLA-A*2402, A*0201, A*0206, A*0207 4) Age between 12 to 79 5) Performance status (ECOG) of 0-2 6) Over 4 weeks after surgery, irradiation, or chemotherapy. 7) Sufficient function of important organs. 8) No uncontrollable pleural, peritoneal or cardiac effusion. 9) Expected survival time: more than 3 months. 10) preventing conception 11) Written informed consents are obtained.

Exclusion criteria

Exclusion criteria: 1) Uncontrollable severe infectious diseases. 2) Serious concomitant diseases 3) Adverse event of NCI-CTC grade 3 or 4. 4) Unable to take anything orally over 24 hours. 5) Active multiple cancers. 6) Myeloproliferative diseases such as MDS and CML. 7) After allogeneic hematopoietic stem cell transplantation. 8) Active autoimmune diseases. 9) Severe drug allergy 10) Necessity for administration of steroid or immunosuppressive drugs. 11) Pregnancy or lactation. Patients hope pregnancy 12) Psychiatric disorders. 13) Unhealed injury. 14) Judged as inappropriate for this study by doctors.

Design outcomes

Primary

Measure	Time frame
Safety and clinical efficacy of Vaccine therapy using VEGFR1 and VEGFR2 peptide for recurrent, progressive and refractory brain tumors	—

Secondary

Measure	Time frame
1 Progression free survival: PFS 2 QoL (Quality of Life):EORTC QLQ-C30,EORTC BN20,MDASI-BT 3 NCF (Neurocognitive Function):MMSE,HVLT-R,TMT,COWA 4 immune reaction (Cytotoxic T lymphocyte(CTL),TCR)	—

Countries

Japan

Contacts

Public ContactMasahiro Toda

Keio university school of medicine Department of Neurosurgery

todam@keio.jp03-5363-3808

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026